Survival News Gilteritinib Triplet Shows 29.7-Month Median Survival in FLT3-Mutated Acute Myeloid Leukemia – Bioengineer.org By Survivalist - November 18, 2026 0 1 Facebook Twitter Pinterest WhatsApp Linkedin Email Advertisment Gilteritinib Triplet Shows 29.7-Month Median Survival in FLT3-Mutated Acute Myeloid Leukemia Bioengineer.org Source link